Water Extract of *Mentha arvensis* L. Attenuates Estrogen Deficiency-Induced Bone Loss by Inhibiting Osteoclast Differentiation

Seon-A Jang, Youn-Hwan Hwang, Hyun Yang, Jin Ah Ryuk, Taesoo Kim and Hyunil Ha*

KM Convergence Research Division, Korea Institute of Oriental Medicine, Daejeon, South Korea

*Mentha arvensis* L., is an aromatic herb that belongs to the Lamiaceae family and is widely used in medicinal applications, essential oil applications, and food flavoring. The extract of *M. arvensis* has been reported to exert sedative-hypnotic, anti-inflammatory, anti-fungal, and anti-bacterial effects. However, its effects on bone metabolism have not yet been studied. Here, we investigated the effects of the water extract of *M. arvensis* (WEMA) on osteoclast formation *in vitro* and bone loss in an ovariectomized mouse model. We found that WEMA inhibited osteoclast differentiation by directly acting on osteoclast precursor cells. WEMA inhibited receptor activator of nuclear factor-κB ligand (RANKL)-induced the expression of cellular oncogene fos (c-Fos) and nuclear factor of activated T cells c1 (NFATc1), crucial transcription factors for osteoclast differentiation, by suppressing RANKL-induced activation of early signaling pathways such as those of mitogen-activated protein kinases (MAPKs) and nuclear factor-κB (NF-κB). In addition, oral administration of WEMA suppressed ovariectomy-induced trabecular bone loss in mice. We additionally identified phytochemicals in WEMA that are known to have anti-osteoclastogenic or anti-osteoporotic properties. Collectively, these results suggest that WEMA is a promising herbal candidate that can be used to prevent or treat postmenopausal osteoporosis.

Keywords: mentha arvensis, osteoporosis, osteoclastogenesis, ovariectomy, RANKL

INTRODUCTION

Bone homeostasis is maintained by a balance between bone resorption and bone formation, mediated by osteoclasts and osteoblasts, respectively. An imbalance in bone homeostasis can occur due to abnormal bone resorption of osteoclasts or loss of osteoblast function. Bone imbalance caused by excessive osteoclast-mediated bone resorption is closely associated with most bone metabolic diseases such as osteoporosis, periodontitis, rheumatoid arthritis, metastatic cancers, and multiple myeloma (Boyle et al., 2003; Tanaka et al., 2005).

Osteoporosis is one of the major health problems in aging communities. There are two types of osteoporosis: type 1 is postmenopausal osteoporosis occurring in postmenopausal women, and type 2 is senile osteoporosis occurring in both women and men over 70 years of age (Boonen et al., 1996). In postmenopausal osteoporosis, loss of trabecular bone is increased, whereas in senile osteoporosis, it increases both the loss of cortical and trabecular bone.
Currently, hormone replacement therapy (HRT) and bisphosphonates are the representative treatments used for postmenopausal osteoporosis. However, long-term HRT has been found to increase the risk of breast cancer, cardiovascular diseases, and biliary disease, and bisphosphonates cause osteonecrosis of the jaw (Nelson et al., 2002; Diel et al., 2007). Therefore, there is a growing interest in the use of natural medicinal plants for therapy that are thought to have few side effects.

Osteoclasts are giant multinucleated cells derived from hematopoietic precursor cells in the bone marrow. Osteoclast precursor cells can differentiate into mature osteoclasts when exposed to the macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-κB ligand (RANKL) (Boyle et al., 2003). RANKL is an essential source of precursor cells that differentiate into osteoclasts, and M-CSF provides the survival of these cells. The binding of RANKL to its receptor promotes the recruitment of tumor necrosis factor receptor-associated factor 6 and activates multiple downstream signaling pathways, including those of nuclear factor-κB (NF-κB) and mitogen-activated protein kinases (MAPKs) including c-Jun N-terminal protein kinase (JNK), p38, and extracellular signal-regulated kinase (ERK). This signaling induces the activation of transcription factors for osteoclastogenesis, namely, c-Fos and nuclear factor of activated T cells c1 (NFATc1), and results in the expression of osteoclast-specific genes such as tartrate-resistant acid phosphatase (TRAP), matrix metalloproteinase-9 (MMP-9), cathepsin K, integrin β3, and calcitonin receptor (Boyle et al., 2003; Wittrant et al., 2003). Inhibition of these molecules could be an effective treatment for osteoporosis by interfering with osteoclast differentiation and bone resorption of activated osteoclasts.

*Mentha arvensis* L., an aromatic herb belonging to the Lamiaceae family, is extensively cultivated in India, Japan, Nepal, Bangladesh, and Sri Lanka for its use in medicinal applications, essential oil applications, and food flavoring (Thawkar, 2016). Previous studies have shown that *M. arvensis* contains various phytochemicals mainly including monoterpene (e.g., menthol, menthone, and isomenthone), phenolic acids (e.g., caffeic acid and rosmarinic acid), and flavonoids (e.g., luteolin, linarin, and hesperidin) (Akram et al., 2011). *M. arvensis* has traditionally been used to treat bacillary dysentery, flatulence, dyspepsia, gastritis, and enteritis. Recently, *M. arvensis* has been reported to have various beneficial biological properties including sedative-hypnotic, anti-inflammatory, anti-fungal, and anti-bacterial activities (Akram et al., 2011). However, the pharmacological properties of the water extract of *M. arvensis* (WEMA) on osteoporosis have not been studied. In this study, we investigated the bone protective effects of WEMA on RANKL-induced osteoclastogenesis and ovariectomy (OVX)-induced postmenopausal osteoporosis.

**MATERIALS AND METHODS**

**Materials**

Cell Counting Kit-8 (CCK-8) was obtained from Dojindo Molecular Technologies Inc. (Rockville, MD, United States). Alpha-modified minimal essential medium (α-MEM) was purchased from HyClone (Logan, UT, United States). Fetal bovine serum (FBS) and calf serum were obtained from Thermo Fisher Scientific (Waltham, MA, United States). 1α,25-dihydroxyvitamin D3 (VitD3) was purchased from Sigma-Aldrich (St. Louis, MO, United States). Recombinant human M-CSF was obtained from Dr. Yongwon Choi (University of Pennsylvania School of Medicine, Philadelphia, PA, United States). Recombinant soluble GST-tagged human RANKL was prepared as previously described (Ha et al., 2013). Antibodies against phospho-IκBα (Ser32), IκBα, phospho-JNK1/2 (Thr183/Tyr185), JNK, phospho-ERK1/2 (thr202/tyr204), ERK, phospho-p38 (Thr180/Tyr182), p38, and β-actin were purchased from Cell Signaling Technology (Danvers, MA, United States). Antibody against aryl hydrocarbon receptor (AhR) was purchased from Enzo Life Sciences, Inc. (Farmingdale, NY, United States). Antibodies against c-Fos and NFATc1 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, United States). WEMA was purchased from the National Development Institute of Korean Medicine (Gyeongsan, Korea). In brief, leaves of *M. arvensis* were extracted with distilled water at reflux for 3 h and dried using a vacuum freeze dryer after filtration. The WEMA powder was resuspended in distilled water, centrifuged at 10,000 × g for 5 min, and stored at −20°C until required for experiment.

**Bone Marrow-Derived Macrophages (BMMs) Isolation**

Bone marrow cells were isolated from 7-week-old male C57BL/6 J mice. The femur and tibia were aseptically extracted, and the marrow cavity was flushed out with α-MEM from one end of the bone using a sterile needle. Single cells obtained from the bone marrow suspension using a cell strainer (70 µm), and red blood cells were lysed for 5 min using Ammonium-Chloride-Potassium (ACK) lysing buffer. The cells were washed twice and incubated with PBS and then BMMs were incubated for 10 min with an Enzyme Free Cell Dissociation Solution (EDM Millipore Corp., Burlington, MA, United States) were cultured in growth α-MEM supplemented with 2.5% FBS, 2.5% calf serum, and 1% penicillin/streptomycin on type I collagen-coated plates for 5 days. Non-adherent cells were removed by washing with PBS and then BMMs were incubated for 10 min with an Enzyme Free Cell Dissociation Solution (EDM Millipore Corp., Burlington, MA, United States), and harvested using a cell lifter.

**Cell Culture**

The murine osteocyte-like cell line, MLO-Y4 cells at 40 passages (Kerafast, Boston, MA, United States) were cultured in growth medium consisting of α-MEM supplemented with 2.5% FBS, 2.5% calf serum, and 1% penicillin/streptomycin on type I collagen-coated plates. MLO-Y4 cells were derived from the long bone of a transgenic mouse expressing a T-antigen transgene under the control of the osteocalcin promoter (Bonevald, 1999), and utilized phenotypic criteria of high osteocalcin expression and morphology consistent with osteocytes. BMMs were cultured in α-MEM supplemented with 10% FBS, 1% penicillin/streptomycin, and M-CSF (60 ng/ml).

**Cell Viability**

The BMMs (2 × 10^4 cells/well) were seeded in 96-well plates and after 12 h, the medium was replaced with α-MEM with or without WAMA (11.1, 33.3, 100, and 200 µg/ml). After 24 h, cell viability
was assessed by a CCK-8 assay, and absorbance was measured at 450 nm using a conventional microplate reader (Molecular Devices, San Jose, CA, United States).

Osteoclast Differentiation

For osteoclast differentiation assay in BMM-osteocyte co-culture, MLO-Y4 (1 × 10^5 cells/well) cells were cultured in a 96-well plate in α-MEM supplemented with 10% FBS and 1% penicillin/streptomycin. The next day, BMMs (4 × 10^4 cells/well) were added to the culture of MLO-Y4, and the co-cultures were cultured with or without WEMA for 5 days in the presence of VitD3 (10 nM) or VitD3 (10 nM) plus RANKL (50 ng/ml). For osteoclast differentiation in BMMs, BMMs (1 × 10^5 cells/well) were cultured with or without WEMA for 4 days in the presence of M-CSF (60 ng/ml) and RANKL (50 ng/ml) in a 96-well plate.

TRAP Activity and Staining

To measure TRAP activity, cells were washed with PBS, fixed using 10% neutral buffered formalin, permeabilized using 0.1% Triton X-100 for, and then incubated using TRAP activity solution (50 mM sodium tartrate, 0.12 M sodium acetate, and p-nitrophenyl phosphate, pH 5.2) for 15 min at 37°C. The reaction was stopped using 0.1N NaOH and the absorbance was measured at 405 nm using a microplate reader. After measuring the TRAP activity, cells were washed with distilled water and stained using TRAP staining solution (50 mM sodium tartrate, 0.12 M sodium acetate, naphthol AS-MX phosphate, and fast red violet LB salt, pH 5.2). Color development was stopped by washing with distilled water. TRAP-positive multinucleated cells (MNCs) containing three or more nuclei were counted as osteoclasts.

Western Blot Analysis

Whole cell proteins were extracted from BMMs using lysis buffer (iNtrION Biotechnology, Sungnam, Korea). Protein concentrations were determined using a standard curve based on the BSA standard reagent that was included in the BCA Protein Assay Kit (ThermoFisher Scientific, MA, United States). The proteins were separated on a 10% SDS-PAGE gel and transferred to a polyvinylidene fluoride membrane. The membranes were blocked with 5% skim milk, incubated with primary antibodies (1:1,000 dilution) against AhR, c-Fos, NFATc1, p-ERK, ERK, p-JNK, JNK, p-p38, p38, p-IκBα, IκBα, or β-actin overnight at 4°C, and then washed 6 times for 5 min each with Tris-buffered saline with 0.1% Tween 20 (TBST) at room temperature. The membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (1:5,000 dilution) for 1 h at room temperature and washed six times with TBST. Specific bands were detected using SuperSignal West Pico Chemiluminescent Substrate and visualized using the ChemiDoc Imaging System (Bio-Rad, Hercules, CA, United States).

Quantitative Real-Time Polymerase Chain Reaction (qPCR)

Total RNA was extracted using the RNA-spin™ Total RNA Extraction Kit (iNtrION Biotechnology, Sungnam, Korea) according to the manufacturer’s instructions. Total RNA (1 μg) was used for cDNA synthesis using a High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific, Waltham, MA, United States). qPCR was performed on an ABI 7500 Real-Time PCR Instrument (Applied Biosystems) after mixing the cDNA (25 ng), TaqMan Universal Master Mix II (Applied Biosystems, Foster City, CA, United States) and TaqMan probe for NFATc1 (Mm00479445_m1), c-Fos (Mm00487425_m1), B lymphocyte-induced maturation protein 1 (Blimp1, Mm00476128_m1), interferon regulatory factor-8 (IRF-8, Mm00492567_m1), v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog B (MafB, Mm00627481_s1), MMP-9 (Mm00442991_m1), integrin β3 (Mm00443980_m1), cathepsin K (Mm00484036_m1), and 18S (Mm99999915_g1). Fold changes in target gene expression were calculated using the ΔΔCt method.

In Vivo Study

All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) at Knotus (Guri, Korea) (approval number: 19-KE-216). Female C57BL/6 J mice (6 weeks old) were housed under standard laboratory conditions of humidity (55% ± 5%), temperature (22°C ± 2°C), and illumination cycle (12 h light/dark cycle). The mice were bilaterally ovariectomized or sham operated through dorsal incisions under Zoletil and Rumpun anesthesia. One week after surgery, healthy mice that recovered from OVX surgery were selected and randomly assigned into four groups (n = 6): sham group, OVX group, OVX + WEMA 100 mg/kg/day treatment group (WEMA-L), and OVX + WEMA 300 mg/kg/day treatment group (WEMA-H). The mice were provided a commercial normal-fat diet (Research Diet, New Brunswick, NJ, United States) and water ad libitum, and WEMA was administered once daily by oral gavage for 5 weeks.

Trabecular Bone Analysis

The distal femurs of mice were fixed by 10% neutral buffered formalin for 2 days and then scanned using a μ-computed tomography (μ-CT) imaging system (Bruker, Kontich, Belgium). After scanning the femur, reconstruction and analysis of the original images were performed using SkyScan NRecon and CTAn software, respectively. Trabecular morphometric parameters including bone mineral density (BMD), bone volume per tissue volume (BV/TV), trabecular thickness (Tb.Th), trabecular number (Tb.N), and trabecular separation (Tb.Sp) were calculated.

Ultrahigh-Performance Liquid Chromatography–Tandem Mass Spectrometry (UHPLC–MS/MS)

A Dionex UltiMate 3,000 system equipped with a Thermo Q-Exactive mass spectrometer was used to analyze the WEMA constituents. Chromatographic separation was achieved using an Acquity BEH C18 column (100 × 2.1mm, 1.7 μm). A gradient elution of the mobile phase using 0.1% formic acid in water (A) and acetonitrile (B) was set as follows: 0–1 min, 3% B; 1–2 min, 3–15% B; 2–13 min, 15–50% B; 13–20 min, 50–100% B; 20–23 min, 100% B; and 23.5–27.5 min, 3% B. The Q-Exactive mass spectrometer was equipped with a heated electrospray ionization source and operated in the positive and negative ionization modes.
ion switching modes, according to a previous study (Hwang et al., 2019). Data acquisition and analysis were performed using Xcalibur v.3.0 and Tracefinder v.3.2 software. Neochlorogenic acid was obtained from ChemFace (Wuhan, China). Danshensu, chlorogenic acid, rutin, isoquercitrin, ferulic acid, hesperidin, rosmarinic acid, and linarin were obtained from Targetmol (Wellesley Hills, MA, United States). The identification of phytochemicals from WEMA was performed by comparing the retention time and mass spectral pattern with reference standards or according to a previous report (Hanafy et al., 2017).

### Statistical Analysis

Data are expressed as mean ± standard deviation (SD) in in vitro experiments and mean ± standard error of the mean (SEM) in animal experiments. Statistical significance was determined by one-way analysis of variance (ANOVA) with Dunnett’s post hoc test or two-way ANOVA with Bonferroni’s post hoc test. Results were considered statistically significant when p values were less than 0.05.

### RESULTS AND DISCUSSION

#### WEMA Inhibits Osteoclast Differentiation

In remodeling bone, osteocytes are the major cells supporting osteoclast differentiation by providing RANKL (Xiong et al., 2015). MLO-Y4, an osteocyte-like cells, can support osteoclast differentiation in co-culture with osteoclast precursor cells (Zhao et al., 2016). WEMA inhibited osteoclast differentiation in MLO-Y4 and bone marrow macrophages (BMMs) under the conditions of RANKL and Vitamin D3 (VitD3) (Figure 1A). WEMA at concentrations of 11.1, 33.3, 100, and 200 μg/ml significantly inhibited osteoclast differentiation after 5 days of culture, as evidenced by a significant reduction in TRAP activity and the number of TRAP-positive multinucleated cells (MNCs) (Figure 1B). BMMs cultured with WEMA showed a dose-dependent decrease in osteoclast formation after 4 days of culture in the presence of RANKL (50 ng/ml) (Figure 1C). Furthermore, WEMA also significantly inhibited osteoclast viability in a dose-dependent manner, indicating its potential antirheumatic properties (Figure 1D). These findings suggest that WEMA may be a promising candidate for the treatment of osteoporosis and related bone diseases.
et al., 2002). To investigate the effect of WEMA on osteoclastogenesis, we first examined whether WEMA affects osteoclast formation in co-culture of MLO-Y4 with osteoclast precursor cells, BMMs. Treatment of the co-culture with VitD3 for 5 days promoted osteoclast differentiation, which was suppressed by WEMA in a dose-dependent manner (Figure 1A). The addition of exogenous RANKL to the co-culture did not recover the inhibitory effect of WEMA, suggesting the possibility of direct action of WEMA on osteoclast precursors. To investigate whether WEMA directly inhibits osteoclastogenesis in osteoclast precursors, osteoclast differentiation was induced by directly adding exogenous RANKL to osteoclast precursor BMMs. Consistent with the results of the co-culture system, WEMA inhibited RANKL-induced osteoclast differentiation of BMMs in a dose-dependent manner (Figure 1B). WEMA did not reduce cell viability of BMMs, indicating that the inhibitory effect of WEMA was not due to cytotoxicity (Figure 1C).

**WEMA Inhibits RANKL-Induced NFATc1 Expression**

To understand the molecular mechanism underlying the anti-osteoclastogenic effect of WEMA, we investigated its effects on key transcription factors required for osteoclastogenesis. RANKL activates NF-κB and MAPKs in osteoclast precursors, and these early signaling pathways lead to the induction of c-Fos and NFATc1. During osteoclastogenesis, the expression of NFATc1 increases and it functions as a master transcription factor for osteoclastogenesis (Takayanagi et al., 2002). WEMA treatment suppressed RANKL-induced expression of NFATc1 mRNA and protein (Figures 2A,B). Activated NFATc1 is known to regulate osteoclast specific genes such as cathepsin K, MMP-9, and integrin β3 which are important for osteoclast differentiation and bone resorption (Boyle et al., 2003). The WEMA inhibited RANKL-induced mRNA expression of cathepsin K, MMP-9, and integrin β3 (Figure 2B). Recently, it was reported that anti-osteoclastogenic transcription factors, such as IRF-8 and MafB, block the transcriptional activity of NFATc1. These factors are negatively regulated by Blimp-1 (Park et al., 2017). WEMA restored reduced IRF-8 and MafB expression accompanied by enhanced Blimp1 expression during RANKL-induced osteoclastogenesis, indicating that WEMA treatment altered Blimp1 signaling to suppress transcription of NFATc1 and its target genes. c-Fos is also upregulated during osteoclastogenesis and plays a key role in the transcriptional induction of NFATc1 (Matsuo et al., 2004). WEMA inhibited RANKL-induced c-Fos protein expression but not mRNA expression. Recently, AhR, a ligand-activated transcription factor, was shown to mediate RANKL-induced MAPK and NF-κB activation and c-Fos induction (Izawa et al., 2016). WEMA did not affect RANKL-induced AhR induction (Figure 2A). Next, we examined whether WEMA affects RANKL-induced activation of early signaling pathways, including those of MAPKs and NF-κB.
FIGURE 3 | WEMA slowed OVX-induced bone loss in mice. The mice were orally administered vehicle or WEMA for 5 weeks. (A) µ-CT images, BMD, and bone morphometric parameters of femoral trabecular bone. (B) Body weight gain and uterine weight. OVX, ovariectomy group; WEMA-L, OVX + WEMA 100 mg/kg/day treatment group; WEMA-H, OVX + WEMA 300 mg/kg/day treatment group; BMD, bone mineral density; BV/TV, bone volume per tissue volume; Tb.N, trabecular number; Tb.Th, trabecular thickness. Tb.Sp, trabecular separation; *p < 0.05, **p < 0.01 versus the OVX group.

| TABLE 1 | Phytochemicals of WEMA by UHPLC-MS/MS. |
| --- | --- | --- | --- | --- | --- | --- | --- |
| No | R<sub>t</sub> (Min) | Calculated (m/z) | Estimated (m/z) | Adducts | Error (ppm) | Elemental composition | MS/MS fragments (m/z) | Identifications |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1 | 4.22 | 197.046 | 197.045 | [M-H]<sup>-</sup> | −4.43 | C<sub>9</sub>H<sub>10</sub>O<sub>5</sub> | 197, 179, 135 | Danshensu<sup>a</sup> |
| 2 | 4.69 | 353.088 | 353.086 | [M-H]<sup>-</sup> | −0.46 | C<sub>16</sub>H<sub>18</sub>O<sub>9</sub> | 191, 179, 135 | Neochlorogenic acid<sup>a</sup> |
| 3 | 5.21 | 353.088 | 353.088 | [M-H]<sup>-</sup> | 0.46 | C<sub>16</sub>H<sub>18</sub>O<sub>9</sub> | 191, 179, 135 | Chlorogenic acid<sup>a</sup> |
| 4 | 6.51 | 609.146 | 609.147 | [M-H]<sup>-</sup> | 0.61 | C<sub>27</sub>H<sub>30</sub>O<sub>16</sub> | 301, 300 | Rutin<sup>a</sup> |
| 5 | 6.78 | 463.088 | 463.088 | [M-H]<sup>-</sup> | 0.25 | C<sub>21</sub>H<sub>20</sub>O<sub>12</sub> | 463, 300, 301 | Isoquercitrin<sup>a</sup> |
| 6 | 7.07 | 193.051 | 193.050 | [M-H]<sup>-</sup> | −3.80 | C<sub>10</sub>H<sub>10</sub>O<sub>4</sub> | 178, 149, 134 | Ferulic acid<sup>a</sup> |
| 7 | 7.58 | 717.146 | 717.147 | [M-H]<sup>-</sup> | 1.63 | C<sub>30</sub>H<sub>34</sub>O<sub>15</sub> | 339, 321, 295 | Salvinolic acid E<sup>a</sup> |
| 8 | 7.9 | 609.183 | 609.183 | [M-H]<sup>-</sup> | 0.11 | C<sub>30</sub>H<sub>34</sub>O<sub>15</sub> | 301 | Hesperidin<sup>a</sup> |
| 9 | 7.99 | 359.077 | 359.077 | [M-H]<sup>-</sup> | −0.51 | C<sub>18</sub>H<sub>20</sub>O<sub>8</sub> | 197, 179, 161 | Rosmarinic acid<sup>a</sup> |
| 10 | 8.22 | 717.146 | 717.146 | [M-H]<sup>-</sup> | 1.71 | C<sub>30</sub>H<sub>34</sub>O<sub>15</sub> | 339, 331 | Salvinolic acid B<sup>a</sup> |
| 11 | 9.51 | 637.177 | 637.176 | [M + HO<sub>2</sub>]<sup>-</sup> | 0.22 | C<sub>28</sub>H<sub>22</sub>O<sub>14</sub> | 283 | Linarin<sup>a</sup> |

<sup>a</sup>Compared with the retention time (R<sub>t</sub>) and mass spectral data of reference standards.
reported that p38 is essential in the initial stages of osteoclastogenesis as it promotes the expression of cathepsin K (Matsumoto et al., 2004). JNK is important for osteoclastogenesis, and ERK plays an important role in osteoclast survival (Miyazaki et al., 2000; David et al., 2002). The NF-κB signaling pathway plays a crucial role in the immune and inflammatory response and is a main downstream signaling pathway involved in RANKL-induced osteoclastogenesis (Boyce et al., 2015; Liu et al., 2017). NF-κB exists as an inactive complex with the NF-κB inhibitor IκBα, which prevents nuclear translocation of NF-κB containing the p50 and p65 subunits. However, upon RANKL stimulation, IKK stimulates the phosphorylation
and degradation of IkBα and liberates NF-κB, leading to its nuclear translocation (Boyce et al., 2015). WEMA inhibited RANKL-induced JNK and p38 MAPKs phosphorylation, but not ERK MAPK, and it also diminished RANKL-induced NF-κB activation, as determined by phosphorylation and degradation of IkBα (Figure 2C). These results suggest that the anti-osteoclastogenic effect of WEMA is, at least in part, attributable to its inhibition of NFATc1 induction by suppressing RANKL-induced early signaling and/or decreasing c-Fos protein levels.

**WEMA Attenuates OVX-Induced Bone Loss in Mice**

Having established that WEMA inhibits osteoclast differentiation, we next examined the effect of WEMA on osteoclast-mediated bone loss in OVX mice. OVX is the most common animal model used to evaluate the mechanisms of postmenopausal osteoporosis and therapeutic strategies for treating this disease. Estrogen deficiency by OVX induces osteoclast differentiation at a rate higher than that of bone formation, which accelerates the turnover rate of bone remodeling, resulting in a decrease in bone mass and deterioration in bone architecture (Komori, 2015). OVX in mice is known to significantly affect trabecular bone but not cortical bone (Komori, 2015). To investigate the effect of WEMA on OVX-induced bone loss, WEMA was orally administered for 5 weeks, starting 1 week after OVX. A new high resolution digital imaging technique μ-CT was used to evaluate trabecular bone quantity and quality by measuring BMD and microstructural parameters including BV/TV, Tb.N, Tb.Th, and Tb.Sp in the distal femurs. Compared with the sham group, OVX mice exhibited a marked trabecular bone loss with a decrease in BMD, BV/TV, Tb.N, and Tb.Th and an increase in Tb.Sp, which was remarkably attenuated by WEMA administration (Figure 3A). As expected, estrogen deficiency by OVX resulted in increased body weight gain and uterine atrophy, and WEMA inhibited OVX-induced increase in body weight gain, but not uterine atrophy (Figure 3B). However, we cannot completely exclude the possible involvement of an estrogen-like activity in exerting the anti-osteoporotic and anti-obesity effects of WEMA, given that phytoestrogens can modulate estrogen receptors (ERs) in a tissue-dependent fashion, due to their differential binding affinities to two ER isoforms, ERα and ERβ (Anandhi Senthilkumar et al., 2018). Taken together, our findings indicate that WEMA can attenuate OVX-induced bone loss and weight gain without exerting an estrogenic effect in the uterus, suggesting that WEMA might be an excellent candidate for the prevention or treatment of postmenopausal osteoporosis and obesity.

**Phytochemical Profiles of WEMA**

To gain insight into the potential underlying mechanisms and biological properties of WEMA, we investigated the phytochemical profiles of WEMA. Previous reports have shown that water extracts of *Mentha* species including *M. arvensis* mainly comprise phenolic acids and flavonoids (Koçar et al., 2004; Fecka and Turek, 2007). In the present study, the UHPLC–MS/MS analysis of WEMA identified eight phenolics (danshensu, neochlorogenic acid, chlorogenic acid, rutin, ferulic acid, salvianolic acid E, rosmarinic acid, and salvianolic acid B) and three flavonoids (isoquercitrin, hesperidin, and linarin) (Table 1). Most phytochemicals were determined by comparing with the retention times and mass fragmentations, and salvianolic acid B and E were tentatively identified according to a previous report (Hanafy et al., 2017). The typical UV base peak chromatograms and the extracted ion chromatograms for each WEMA analyte are shown in Figure 4. These phytochemicals, except neochlorogenic acid and salvianolic acid E, have been reported to show bone protective properties in *vitro* and/or in *vivo*. Chlorogenic acid, ferulic acid, and linarin have been shown to inhibit osteoclast differentiation in *vitro* by interfering with RANKL-induced NF-κB activation and NFATc1 induction (Kwak et al., 2013; Omori et al., 2015; Doss et al., 2018; Wang et al., 2018). Danshensu, rutin, isoquercitrin, ferulic acid, hesperidin, rosmarinic acid, and salvianolic acid B were shown to attenuate OVX or RANKL-induced bone loss in *vitro* (Horcajada-Molteni et al., 2000; Chiba et al., 2003; Sassa et al., 2003; Lee et al., 2015; Qu et al., 2016; Liu and Shen, 2018; Fayed et al., 2019). In addition, danshensu, rutin, isoquercitrin, ferulic acid, hesperidin, rosmarinic acid, salvianolic acid B, and linarin were observed to promote osteoblast differentiation (Huan-qiong and Liao, 2008; Trzeciakiewicz et al., 2010; Li et al., 2016; Du et al., 2017; Zhang et al., 2017; Li et al., 2019; Jeong et al., 2021; Liu et al., 2021). Thus, these findings suggest that the beneficial effects of these phytochemicals may account for the anti-osteoclastogenic and anti-osteoporotic effects of WEMA.

**CONCLUSION**

This study is the first to show the beneficial effects of WEMA on bone health. WEMA inhibited osteoclast differentiation by suppressing RANK signaling to NFATc1 induction in osteoclast precursor cells. In a postmenopausal mouse model, WEMA exhibited beneficial effects on bone loss and weight gain without promoting uterine hypertrophy. In addition, we detected phytochemicals in WEMA that have anti-osteoclastogenic or anti-osteoporotic properties. Collectively, these results suggest that WEMA is a promising herbal candidate that can be used to prevent or treat postmenopausal osteoporosis.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

**ETHICS STATEMENT**

The animal study was reviewed and approved by Institutional Animal Care and Use Committee at Knotus (Guri, Korea).
AUTHOR CONTRIBUTIONS

HH conceived the study and designed the experiments. S-AJ, Y-HH, HY, JR, and TK performed the experiments. S-AJ wrote and revised the manuscript. All authors read and approved the final manuscript.

REFERENCES

Akram, M., Uzair, M., Malik, N. S., Mahmood, A., Sarwer, N., Madni, A., et al. (2011). Mentha Arvensis Linn.: A Review Article. J. Med. Plant Res. 5, 4499–4503. doi:10.5897/jmpr11.1198

Anandhi Senthilkumar, H., Fata, J. E., and Kennelly, E. J. (2018). Phytoestrogens: The Current State of Research Emphasizing Breast Pathophysiology. Phytotherapy Res. 32, 1707–1719. doi:10.1002/ptr.6115

Bowned, L. F. (1999). Establishment and Characterization of an Osteocyte-like Cell Line, MLO-Y4. J. Bone Mineral Metab. 17, 61–65. doi:10.1007/s007740050066

Boonen, S., Brooks, P., and Dequeker, J. (1996). Age-related Factors in the Pathogenesis of Senile (Type II) Femoral Neck Fractures. Am. J. Orthop. (Belle Mead NJ) 25, 198–204.

Boyle, W. J., Simonet, W. S., and Lacey, D. L. (2003). Osteoclast Differentiation and Activation. Nature 423, 337–342. doi:10.1038/nature01658

Chiba, H., Uehara, M., Wu, J., Masuyama, R., Suzuki, K., et al. (2003). Chlorogenic Acid Inhibits Osteoclast Differentiation and Bone Resorption by Down-Regulation of Receptor Activator of Nuclear Factor Kappa-B Ligand-Induced Nuclear Factor of Activated T Cells C1 Expression. Biol. Pharm. Bull. 26, 1779–1786. doi:10.1248/bpb.13-0430

Du, K., Li, Z., Fang, X., Cao, T., and Xu, Y. (2017). Ferulic Acid Promotes the Osteogenic Differentiation of Osteoblasts and BMSCs via the Inhibition of Runt-related Activator of Transcription 3. Mol. Nutr. Food Res. 61, 1897–1907. doi:10.1002/mnfr.201400164

Doss, H. M., Samarrita, S., Ganesan, R., and Rasool, M. (2018). Ferrulic Acid, a Dietary Polyphenol Suppresses Osteoclast Differentiation and Bone Erosion via the Inhibition of RANKL. J. Cell. Biochem. 119, 294–304. doi:10.1002/jcb.28560

Fecka, I., and Turek, S. (2007). Determination of Water-Soluble Polyphenolic Compounds in Commercial Herbal Teas from Lamiaceae: Peppermint, melissa, and sage. J. Agric. Food Chem. 55, 10908–10917. doi:10.1021/jf072284d

Hanafy, D. M., Prenzler, P. D., Burrows, G. E., Ryan, D., Nielsen, S., El Sawi, S. A., et al. (2017). Biophenols of Mints: Antioxidant, Acetylcholinesterase, Butyrylcholinesterase and Histone Deacetylase Inhibition Activities Targeting Alzheimer’s Disease Treatment. J. Funct. Foods 33, 345–362. doi:10.1016/j.jff.2017.03.027

Hortalá-Moltén, M.-N., Crespy, V., Cozam, V., Davicco, M.-J., REMÉSY, C., and Barlet, J.-P. (2000). Rutin Inhibits Ovariectomy-Induced Osteopenia in Rats. J. Bone Miner. Res. 15, 2251–2258. doi:10.1359/jbmr.2000.15.11.2251

Huan-Qiong, F., and Liao, C. (2008). Effects of Salvianolic Acid B on Osteoblast In Vitro. Chin. Pharmcol. Bull. 7.

FUNDING

This research was funded by the Korea Institute of Oriental Medicine, Ministry of Education, Science and Technology, Korea (Grant number KSN2013330).

Hwang, Y. H., Jang, S. A., Kim, T., and Ha, H. (2019). Forsythia Suspensa Protects against Bone Loss in Ovariectomized Mice. Nutrients 11 (8), 1831. doi:10.3390/nu11081831

Izawa, T., Arakaki, R., Mori, H., Tsunematu, T., Kudo, Y., Tanaka, E., et al. (2016). The Nuclear Receptor AhR Controls Bone Homeostasis by Regulating Osteoclast Differentiation via the RANKL-c-Fos Signaling Axis. J. Biol. Chem. 291, 4639–4650. doi:10.1074/jbc.M11608822

Jeong, M.-J., Lim, D.-S., Kim, S. O., Park, C., Choi, Y. H., and Jeong, S.-J. (2021). Effect of Rosmarinic Acid on Differentiation and Mineralization of MC3T3-E1 Osteoblastic Cells on Titanium Surface. Anim. Cell Syst. 25, 46–55. doi:10.1080/19783534.2021.1886987

Košar, M., Dorman, H. J., Can Başer, K. H., and Hiltunen, R. (2004). Screening of Free Radical Scavenging Compounds in Water Extracts of Menthana Samples Using a Postcolumn Derivatization Method. J. Agric. Food Chem. 52, 5004–5010. doi:10.1021/jf0496189

Kwak, S. C., Lee, C., Kim, J.-Y., Oh, H. M., So, H.-S., Lee, M. S., et al. (2013). Chlormogenic Acid Inhibits Osteoclast Differentiation and Bone Resorption by Down-Regulation of Receptor Activator of Nuclear Factor kappa-B Ligand-Induced Nuclear Factor of Activated T Cells C1 Expression. Biol. Pharm. Bull. 36, 1779–1786. doi:10.1248/bpb.b13-04430

Lee, J.-W., Asai, M., Jeon, S.-K., Imura, T., Yonezawa, T., Cha, B.-Y., et al. (2015). Rosmarinic Acid Exerts an Antiestrogenic Effect in the RANKL-Induced Mouse Model of Bone Loss by Promotion of Osteoblastic Differentiation and Inhibition of Osteoclastic Differentiation. Mol. Nutr. Food Res. 59, 386–400. doi:10.1002/mnfr.201400164

Li, J., Hao, L., Wu, J., Zhang, J., and Su, J. (2016). Linarin Promotes Osteogenic Differentiation by Activating the BMP-2/RUNX2 Pathway via Protein Kinase A Signaling. Int. J. Mol. Med. 37, 901–910. doi:10.3892/ijmm.2016.2490

Li, M., Zhang, C., Li, X., Lv, Z., Chen, Y., and Zhao, J. (2019). Isoquercitrin Promotes the Osteogenic Differentiation of Osteoblasts and BMSCs via the RUNX2 or BMP Pathway. Connect. Tissue Res. 60, 189–199. doi:10.1080/03008270.2018.1483538

Liu, T., Zhang, L., Foo, D., and Sun, S.-C. (2017). NF-kB Signaling in Inflammation. Signal. Transduct. Target. Ther. 2, 1–9. doi:10.1038/sigtrans.2017.23

Liu, X. W., Ma, B., Zl, Y., Xiang, L. B., and Han, T. Y. (2021). Effects of Rutin on Osteoblast MC3T3-E1 Differentiation, ALP Activity and Runx2 Protein Expression. Eur. J. Histochem. 65 (1), 3195. doi:10.4081/ejh.2021.3195

Liu, Y., and Shen, H. (2018). Salvinanolic Acid B Administration Attenuates Bone Loss in Ovariectomy Induced Rat Model. Int. J. Pharmacol. 14, 866–872. doi:10.3923/ijp.2018.886.872

Matsumoto, M., Kogawa, M., Wada, S., Takayanagi, H., Tsujimoto, M., Katayama, S., et al. (2004). Essential Role of P38 Mitogen-Activated Protein Kinase in Catepsin K Gene Expression during Osteoclastogenesis through Association of NFATc1 and P.U.1. J. Biol. Chem. 279, 45969–45979. doi:10.1074/jbc.M408795200

Matsuo, K., Galson, D. L., Zhao, C., Peng, L., Laplace, C., Wang, K. Z. Q., et al. (2004). Nuclear Factor of Activated T-Cells (NF-AT) Rescues Osteoclastogenesis in Precursors Lacking C-Fos. J. Biol. Chem. 279, 26475–26480. doi:10.1074/jbc.M403973200

Miyazaki, T., Katagiri, H., Kanegae, Y., Takayanagi, H., Sawada, Y., Yamamoto, A., et al. (2000). Reciprocal Role of ERK and Nf-κB Pathways in Survival and Activation of Osteoclasts. J. Cell Biol. 148, 333–342. doi:10.1083/jcb.148.2.333

Nelson, H. D., Humphrey, L. L., Nygren, P., Teutsch, S. M., and Allan, J. D. (2002). Postmenopausal Hormone Replacement Therapy. JAMA 288, 872–881. doi:10.1001/jama.288.7.872

Omori, A., Yoshimura, Y., Deyama, Y., and Suzuki, K. (2015). Rosmarinic Acid and Arbutin Suppress Osteoclast Differentiation by Inhibiting Superoxide and...
NFATc1 Downregulation in RAW 264.7 Cells. *Biomed. Rep.* 3, 483–490. doi:10.3892/br.2015.452

Park, J. H., Lee, N. K., and Lee, S. Y. (2017). Current Understanding of RANK Signaling in Osteoclast Differentiation and Maturation. *Mol. Cell* 40, 706–713. doi:10.14348/molcells.2017.0225

Qu, T., Zheng, P., Yang, C., Lan, X., Zhang, T., Liu, H., et al. (2016). Effects of Danshensu on Bone Formation in Ovariectomized Rats. *Zhejiang Da Xue Xue Bao Yi Xue Ban* 45, 587–591. doi:10.3785/j.issn.1008-9292.2016.11.05

Sassa, S., Kikuchi, T., Shinoda, H., Suzuki, S., Kudo, H., and Sakamoto, S. (2003). Preventive Effect of Ferulic Acid on Bone Loss in Ovariectomized Rats. *In Vivo* 17, 277–280.

Takayanagi, H., Kim, S., Koga, T., Nishina, H., Ishida, M., Yoshida, H., et al. (2002). Induction and Activation of the Transcription Factor NFATc1 (NFAT2) Integrate RANKL Signaling in Terminal Differentiation of Osteoclasts. *Dev. Cel* 3, 889–901. doi:10.1016/s1534-5807(02)00369-6

Tanaka, Y., Nakayamada, S., and Okada, Y. (2005). Osteoblasts and Osteoclasts in Bone Remodeling and Inflammation. *Cdtia* 4, 325–328. doi:10.2174/1568010054022015

Thawkar, B. S. (2016). Phytochemical and Pharmacological Review of Mentha Arvensis. *Int. J. Green. Pharm.* 10. doi:10.22377/ijgp.v10i2.643

Trzeciakiewicz, A., Habauzit, V., Mercier, S., Lebecque, P., Davicco, M.-J., Coxam, V., et al. (2010). Hesperetin Stimulates Differentiation of Primary Rat Osteoblasts Involving the BMP Signalling Pathway. *J. Natr. Biochem.* 21, 424–431. doi:10.1016/j.jnmbio.2009.01.017

Wang, J., Fu, B., Lu, F., Hu, X., Tang, J., and Huang, L. (2018). Inhibitory Activity of Linarin on Osteoclastogenesis through Receptor Activator of Nuclear Factor kB Ligand-Induced NF-kB Pathway. *Biochem. Biophysical Res. Commun.* 495, 2133–2138. doi:10.1016/j.bbrc.2017.12.091

Witrant, Y., Theoleyre, S., Couillaud, S., Dunstan, C., Heymann, D., and Rédini, F. (2003). Regulation of Osteoclast Protease Expression by RANKL. *Biochem. Biophysical Res. Commun.* 310, 774–778. doi:10.1016/j.bbrc.2003.09.084

Xiong, J., Piemontese, M., Onal, M., Campbell, J., Goellner, J. J., Dusevich, V., et al. (2015). Osteocytes, Not Osteoblasts or Lining Cells, Are the Main Source of the RANKL Required for Osteoclast Formation in Remodeling Bone. *PLoS One* 10, e0138189. doi:10.1371/journal.pone.0138189

Zhang, X., Zou, L., Li, J., Xu, B., Wu, T., Fan, H., et al. (2017). Salvianolic Acid B and Danshensu Induce Osteogenic Differentiation of Rat Bone Marrow Stromal Stem Cells by Upregulating the Nitric Oxide Pathway. *Exp. Ther. Med.* 14, 2779–2788. doi:10.3892/etm.2017.4914

Zhao, S., Kato, Y., Zhang, Y., Harris, S., Ahuja, S. S., and Bonewald, L. F. (2002). MLO-Y4 Osteocyte-like Cells Support Osteoclast Formation and Activation. *J. Bone Miner. Res.* 17, 2068–2079. doi:10.1359/jbmr.2002.17.11.2068

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Jang, Hwang, Yang, Ryuk, Kim and Ha. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.